#Israel #Caesarea #IceCure Medical #Cryoablation #ProSense

IceCure’s ProSense® Cryoablation Shines at RSNA 2025

IceCure Medical Ltd. has recently marked a significant milestone in the field of breast cancer treatment with its ProSense® Cryoablation system. Featured in four independent studies at the Radiological Society of North America's (RSNA) 2025 Annual Meeting, the technology demonstrates unprecedented effectiveness and highlights its growing acceptance in the medical community as a non-surgical option for breast cancer treatment.

Overview of Research Presentations

The RSNA, the largest radiology conference globally, hosted approximately 50,000 participants from 160 countries. This year’s event underscored the value of research presented through four distinct abstracts that collectively focused on various aspects of ProSense technology, with findings based on a substantial cohort of 263 patients.

Eyal Shamir, CEO of IceCure Medical, emphasized the importance of these independent studies, stating, "The broad range of independent studies conducted, peer-reviewed, published, and presented by ProSense users supports the wide-scale adoption of our cryoablation system. This presents highly encouraging news for women seeking non-surgical treatment options."

Highlights from the Studies

1. Ultrasound-guided Cryoablation for Non-Surgical Patients: This study, conducted in Spain, showcased a 100% success rate for treating luminal cancers up to 2.5 cm. The research included 73 patients, and it reported a complete tumor necrosis rate of 81.2%, underscoring the procedure’s safety and efficacy for early-stage breast cancer.

2. Comparative Outcomes of Non-Surgical Treatments: A pivotal Italian study compared cryoablation combined with hormonal therapy to singular treatments, revealing that the combination significantly reduced tumor sizes more effectively than either treatment alone. Notably, the study indicated that patients received an average tumor reduction of 13.6 mm with combined treatment.

3. Assessment of Cryoablation Outcome Through CEM: The correlation of lesion conspicuity in contrast-enhanced mammography (CEM) with biopsy results demonstrated that lower conspicuity levels correlate with more favorable cryoablation outcomes. This research reinforced the predictive capabilities of CEM in assessing treatment success.

4. Imaging Findings Post-Cryoablation: The final study offered insights into identifying successful cryoablation through imaging techniques, valuable for ongoing monitoring without the need for recurrent biopsies.

Significance of ProSense® Cryoablation

ProSense is the first device to gain FDA marketing authorization for treating low-risk breast cancer in patients unable or unwilling to undergo surgical procedures. Utilizing liquid nitrogen, ProSense effectively creates large lethal zones that target and destroy both benign and malignant tumors.

Shamir reinforced IceCure's commitment to enhancing patient care by stating, "With ProSense, we are not just offering an effective method for tumor destruction; we are also improving patient experience by minimizing recovery times and complications related to traditional surgical interventions."

Future Implications

The promising results from the RSNA presentations highlight a shifting paradigm in breast cancer treatment, moving increasingly towards less invasive methods. With a rapidly growing interest following its FDA approval and the positive feedback from global radiology professionals, IceCure Medical is positioned to make significant contributions to oncological practices.

This year’s RSNA served not only as a platform for showcasing technological advancements but also affirmed the medical community's enthusiasm for ProSense. IceCure aims to continue redefining treatment standards and improving outcomes for patients in need of less invasive cancer care solutions. The ongoing commitment to innovation in cryoablation technology could lead to enhanced adoption rates and broaden the spectrum of effective treatment options available for breast cancer patients.

As the medical field embraces new technologies, IceCure's ProSense® Cryoablation stands out as a beacon of hope, providing effective, non-surgical solutions that significantly enhance patient recovery and quality of life.